Drugs / PF-04217903
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00706355 | Aug 2008 → Jun 2011 | neoplasm | Pfizer | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04217903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00706355 ↗ |
| Known as | MET TYROSINE KINASE INHIBITOR PF-04217903 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2001019 ↗ |
| Known as | PF-4217903 | “Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-4217903 in Patients With Advanced Cancer” NCT00706355 ↗ |
| Action | Inhibit | “PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells.” NCT00706355 ↗ |
| Modality | Small molecule | — CHEMBL2001019 ↗ |
| Route | Oral | “PF-04217903 is taken by mouth daily.” NCT00706355 ↗ |
| Target | MET | “PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors.” NCT00706355 ↗ |